Histone deacetylase (HDAC) inhibitors are expected to be effective for refractory cancer because their mechanism of action differs from that of conventional antineoplastic agents. In this study, we ...
LPA and S1P: intercellular lipid mediators acting on specific GPCRs LPA and thrombin were the first GPCR agonists shown to rapidly stimulate Ras-GTP accumulation in quiescent mammalian cells (van ...
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025 Potential U.S. commercial ...
As many as 50 percent of human cancer cases -- across a wide variety of tissues -- involve defects in a common cellular growth signaling pathway. These defects have so far defied most attempts to ...
Erasca, Inc. focuses on developing novel targeted therapies for solid tumors, particularly through the RAS/MAP kinase pathway, with a promising yet early-stage pipeline. The company’s lead program, ...
Uncovering the differential impact of ESR1 and PIK3CA codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback